ISO 14971:2019 - Medical Device Risk Management Implementer Free Practice Test — 30 Questions

Question 1

When evaluating potential risk control measures for a novel diagnostic imaging device, which fundamental principle, as outlined in ISO 14971:2019, should guide the selection and implementation sequence to achieve the most robust risk reduction?

Accepted Answer

Prioritize inherent safety by design, followed by protective measures, and lastly, information for safety.

Question 2

During the post-market surveillance of a novel implantable cardiac defibrillator, a critical failure mode is identified where the device\'s battery unexpectedly depletes significantly faster than predicted, leading to a loss of pacing function. This failure mode was previously addressed by a specific risk control measure designed to monitor battery health and alert the patient. However, post-market data indicates that the monitoring system itself is prone to intermittent software glitches, preventing timely alerts. Considering the principles of ISO 14971:2019, what is the most appropriate immediate action for the manufacturer\'s risk management team?

Accepted Answer

Update the risk management file to document the ineffectiveness of the battery monitoring risk control measure, re-evaluate the risk associated with premature battery depletion, and reassess the acceptability of the overall residual risk.

Question 3

A manufacturer of an implantable cardiac rhythm management device is proposing a software update to enhance battery life monitoring. While the primary intent is to improve user experience by providing more accurate remaining battery estimates, the update involves modifying the algorithm that processes sensor data. What is the most critical risk management action the implementer must undertake before deploying this software update, considering the principles outlined in ISO 14971:2019 and relevant regulatory expectations for post-market surveillance and change control?

Accepted Answer

Conduct a comprehensive risk assessment of the proposed software modification, including the identification of new hazards and the re-evaluation of existing risks, and subsequently update the risk management file.

Question 4

A manufacturer is developing a novel implantable cardiac rhythm management device. During the design phase, a critical decision is made to switch from a traditional lithium-ion battery to a solid-state battery technology to enhance longevity and safety. This change significantly impacts the device\'s internal architecture, thermal characteristics, and potential failure modes. According to ISO 14971:2019, what is the most appropriate action for the risk management team to undertake immediately following this fundamental design change?

Accepted Answer

Initiate a complete re-evaluation of the risk management file, including hazard identification, risk analysis, risk evaluation, and risk control measures, to address the implications of the new battery technology.

Question 5

A manufacturer of an implantable cardiac rhythm management device has developed a significant software update for their existing product line. This update introduces a novel algorithm designed to improve pacing efficiency, but it also alters the device\'s response to certain external electromagnetic interference (EMI) signals, potentially leading to unintended pacing modes. According to ISO 14971:2019, what is the most appropriate action the manufacturer must take regarding their risk management process after developing this software update?

Accepted Answer

Conduct a full re-evaluation of the device's risks, update the risk management file, and verify the effectiveness of risk control measures for the modified device.

Question 6

Following the successful market introduction of a novel implantable cardiac rhythm management device, the manufacturer identifies a need to deploy a software update to enhance battery management algorithms. This update is intended to extend device longevity and does not alter the device\'s primary therapeutic functions. Considering the requirements of ISO 14971:2019, what is the most appropriate risk management action to undertake *before* the software update is released to patients via a service provider?

Accepted Answer

Conduct a thorough risk analysis of the updated software, identifying new hazards, estimating associated risks, and evaluating their acceptability, documenting these findings in the risk management file.

Question 7

A manufacturer of a novel implantable cardiac monitor, initially cleared for monitoring atrial fibrillation in adult patients, decides to expand its intended use to include continuous monitoring of ventricular arrhythmias in pediatric patients. This expansion involves minor software adjustments to alter data sampling rates and alert thresholds. Considering the principles of ISO 14971:2019, what is the most critical step the risk management team must undertake *before* proceeding with the expanded intended use?

Accepted Answer

Conduct a thorough re-evaluation of all identified hazards and associated risks, updating the risk management file to reflect the new pediatric patient population and altered monitoring parameters, and verify the continued acceptability of residual risks.

Question 8

A medical device manufacturer has successfully completed the design and development phase for a novel implantable cardiac stimulator, with all identified risks documented and mitigated according to ISO 14971:2019. As the company prepares to transition to full-scale production, what is the paramount consideration for the risk management team to ensure continued compliance and patient safety?

Accepted Answer

Verifying the effectiveness of risk control measures within the manufacturing environment and updating the risk management plan to reflect production realities.

Question 9

Following the implementation of a new risk control measure designed to mitigate a specific identified hazard associated with a novel diagnostic imaging device, the risk analysis team has confirmed that the risk associated with that particular hazard has been reduced to an acceptable level. However, the team is still in the process of evaluating the cumulative impact of all implemented risk control measures on the overall residual risk of the device. What is the most critical next step in the risk management process according to ISO 14971:2019?

Accepted Answer

Re-evaluate the overall residual risk of the medical device.

Question 10

Following the successful market launch of a novel implantable cardiac rhythm management device, the manufacturer receives multiple reports through their post-market surveillance system detailing an unexpected, transient loss of pacing capture in a small but statistically significant subset of patients under specific environmental conditions not previously identified during pre-market testing. What is the most appropriate immediate action for the manufacturer to take in accordance with ISO 14971:2019 principles and general regulatory expectations for post-market data?

Accepted Answer

Initiate a comprehensive review of the risk management file, specifically re-evaluating the risk analysis and risk evaluation for the identified hazard, and implement necessary risk control measures or updates to existing ones.

Question 11

A manufacturer of an implantable cardiac pacemaker is preparing to release a significant firmware update designed to improve battery efficiency and introduce a new diagnostic feature. This update involves modifications to the device\'s internal algorithms and the communication protocol used for data retrieval. Considering the stringent requirements of ISO 14971:2019 for medical device risk management, what is the most appropriate action the manufacturer must take regarding their risk management activities *before* deploying this firmware update to the market?

Accepted Answer

Conduct a comprehensive re-evaluation of all identified hazards, hazardous situations, and associated risks, updating the risk management file to reflect the potential impact of the firmware changes on the device's safety and performance.

Question 12

A manufacturer of an implantable cardiac defibrillator (ICD) has developed a new firmware update designed to improve battery longevity by adjusting the pacing algorithm. This update is considered a significant modification to the device\'s operational parameters. According to ISO 14971:2019, what is the primary risk management activity that must be undertaken by the manufacturer upon the development of this firmware update, prior to its release to the market?

Accepted Answer

A comprehensive re-evaluation of the risk management file to identify new hazards or changes in risk associated with the modified pacing algorithm and its impact on the device's overall safety.

Question 13

A manufacturer of a novel diagnostic imaging system, initially intended for use in a controlled hospital laboratory environment, receives regulatory approval to expand its intended use to include point-of-care testing in diverse clinical settings. This expansion involves modifications to the device\'s power supply and user interface to accommodate mobile operation. According to ISO 14971:2019, what is the most critical immediate action the manufacturer must undertake regarding their risk management process following this approval and the planned modifications?

Accepted Answer

Initiate a comprehensive re-evaluation of all identified hazards and associated risks, update the risk management plan and file to reflect the expanded intended use and modifications, and verify the effectiveness of existing and any new risk control measures.

Question 14

A manufacturer of an implantable cardiac rhythm management device is planning to release a firmware update that introduces a novel algorithm for detecting and responding to atrial fibrillation. This update is intended to improve patient outcomes by offering more personalized pacing strategies. Considering the lifecycle approach to risk management mandated by ISO 14971:2019 and the regulatory expectations for post-market surveillance and change control, what is the most critical step the manufacturer must undertake *before* releasing this firmware update to the market?

Accepted Answer

Conduct a thorough re-evaluation of all identified hazards and risks, including those associated with the new algorithm and its interactions with existing device functions, and implement/verify necessary risk control measures.

Question 15

Consider a scenario where a Class II medical device, initially approved with a conventional optical sensor for patient monitoring, is subsequently redesigned to incorporate a novel bio-impedance sensing technology. This change significantly alters the device\'s data acquisition method and introduces new potential failure modes related to electrical conductivity and tissue interaction. According to the principles outlined in ISO 14971:2019, what is the most appropriate risk management action to take following this substantial design modification?

Accepted Answer

Conduct a comprehensive re-evaluation of the entire risk management file, including hazard identification, risk analysis, risk evaluation, and risk control measures for the modified device.

Question 16

A manufacturer of an implantable cardiac rhythm management device discovers through post-market surveillance data that a specific batch of components, while not directly linked to any reported adverse events, exhibits a statistically significant increase in a particular electrical characteristic deviation compared to historical norms. This deviation, if it were to manifest in a higher proportion of devices, could theoretically lead to a reduced battery lifespan, potentially impacting the device\'s ability to deliver therapy. What is the most appropriate immediate action according to the principles of ISO 14971:2019?

Accepted Answer

Initiate a review of the risk management file, reassessing the effectiveness of risk control measures related to component sourcing and electrical performance, and consider implementing additional controls or design modifications if residual risk is deemed unacceptable.

Question 17

A manufacturer of an implantable cardiac defibrillator (ICD) receives multiple post-market reports detailing instances where the device\'s lead integrity monitoring system failed to detect a lead fracture, leading to a loss of therapy delivery. The manufacturer\'s risk analysis had identified lead fracture as a hazard with a risk control measure in place to monitor lead integrity. How should the manufacturer proceed to address these reports in accordance with ISO 14971:2019 principles?

Accepted Answer

Conduct a re-evaluation of the risk management process for the identified hazard of lead fracture, focusing on the effectiveness of the lead integrity monitoring system and updating the risk management file accordingly.

Question 18

A manufacturer of a novel implantable cardiac defibrillator (ICD) has received regulatory approval for its initial intended use: treatment of ventricular fibrillation in adult patients. Following several years of successful post-market surveillance, the manufacturer identifies a potential for improved patient outcomes by adapting the device\'s algorithm to also manage certain types of supraventricular tachycardias. This adaptation involves a modification to the device\'s firmware and a proposed expansion of the labeling to include this new indication. According to ISO 14971:2019, what is the most appropriate risk management action to take prior to implementing this proposed change?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, including re-evaluation of identified hazards, risk analysis, risk evaluation, and risk control measures for the modified device and its new intended use.

Question 19

A manufacturer of a portable diagnostic device decides to implement a new battery technology to extend operational time between charges. This modification involves a different chemical composition and a revised charging circuit. According to ISO 14971:2019, what is the mandatory risk management action required when such a significant design change is introduced?

Accepted Answer

Conduct a complete re-evaluation of all identified hazards and associated risks, updating the risk management file to reflect the impact of the new battery technology and charging circuit.

Question 20

A manufacturer of an advanced implantable cardiac rhythm management device decides to incorporate a new wireless data transmission module to facilitate remote patient monitoring. This modification involves significant changes to the device\'s internal architecture and power management system. What is the most critical step in the risk management process to ensure continued patient safety and regulatory compliance, given this substantial design alteration?

Accepted Answer

Conduct a thorough re-evaluation of all identified hazards and risks, and update the risk management file to reflect the impact of the new module on the device's safety, including the potential for electromagnetic interference and data security breaches.

Question 21

Following the successful market launch of a novel implantable cardiac monitor, new post-market surveillance data emerges indicating a statistically significant, albeit low, incidence of unexpected device deactivation during strenuous physical activity. Concurrently, the manufacturer is exploring an expansion of the device\'s intended use to include monitoring patients undergoing rigorous athletic training. Which of the following actions is most critical to ensure ongoing compliance with ISO 14971:2019 and relevant medical device regulations, such as the EU MDR?

Accepted Answer

Update the risk management file to incorporate the new post-market surveillance findings and reassess the risks associated with the expanded intended use.

Question 22

A manufacturer of a novel implantable cardiac defibrillator (ICD) receives post-market surveillance data indicating a higher-than-anticipated rate of lead dislodgement in patients over 75 years of age, a demographic not heavily represented in the initial clinical trials. This dislodgement, while rare, can lead to a loss of therapy and potential patient harm. The manufacturer\'s initial risk assessment had classified lead dislodgement as a low-probability, high-severity event, with existing risk control measures focused on surgical technique and device design to prevent initial securement.

Which of the following actions is the most appropriate response according to the principles of ISO 14971:2019 for managing this emerging risk?

Accepted Answer

Conduct a thorough review of the risk management file, update the risk analysis to incorporate the new data on lead dislodgement in the specified patient population, reassess the risk acceptability, and implement additional risk control measures if necessary, documenting all changes.

Question 23

A manufacturer of a diagnostic imaging device, initially intended for use in a hospital setting by trained radiologists, plans to adapt it for point-of-care diagnostics in a primary care physician\'s office. This adaptation involves simplifying the user interface and enabling remote operation by less specialized personnel. Considering the principles of ISO 14971:2019, what is the most critical action the manufacturer must undertake regarding the existing risk management file for this device?

Accepted Answer

Conduct a comprehensive re-evaluation of all identified hazards and hazardous situations, considering the new intended use environment and user profile, and update the risk management plan and report accordingly.

Question 24

Following a significant software update to a Class II implantable cardiac pacemaker, which action is most critical to ensure continued compliance with ISO 14971:2019 and relevant regulatory requirements such as the EU MDR (Regulation (EU) 2017/745)?

Accepted Answer

Re-execute the entire risk analysis process, including hazard identification, estimation of risks, and evaluation of risks for all identified hazards, and verify the effectiveness of existing and potentially new risk control measures.

Question 25

A manufacturer of a diagnostic imaging device, initially intended for use in hospital radiology departments, is now exploring an expanded intended use for point-of-care diagnostics in primary care settings. This expansion involves a modified user interface and a different power source. According to ISO 14971:2019, what is the most appropriate action the manufacturer must take regarding their existing risk management process?

Accepted Answer

Initiate a complete reassessment of the risk management file, including re-evaluation of hazards, risk estimation, risk evaluation, and risk control measures for the device in its new intended use environment.

Question 26

A manufacturer of an implantable cardiac defibrillator receives reports from post-market surveillance indicating a statistically significant increase in the incidence of lead dislodgement, a hazard previously identified but considered to have a low probability of occurrence. This new data suggests the probability may be higher than initially assessed. What is the most appropriate immediate action according to ISO 14971:2019 for the risk management implementer?

Accepted Answer

Initiate a review of the risk management file and the risk management plan to incorporate the new data on lead dislodgement and reassess the risk acceptability.

Question 27

Following the implementation of a specific risk control measure for a novel diagnostic imaging device, the risk analysis team is reviewing the updated risk assessment. The initial risk assessment identified a potential hazard with a severity rating of \"Critical\" and an occurrence probability of \"Frequent.\" After implementing a software-based error detection algorithm as a risk control measure, the estimated occurrence probability for that specific hazard has been reduced to \"Improbable.\" The established risk acceptability criteria state that any hazard with a \"Critical\" severity must have an occurrence probability of \"Remote\" or less to be considered acceptable. What is the immediate next step required by ISO 14971:2019 in this scenario?

Accepted Answer

Re-evaluate the acceptability of the residual risk based on the updated occurrence probability and the established risk acceptability criteria.

Question 28

A manufacturer of an implantable cardiac defibrillator (ICD) has completed its initial risk analysis for a potential failure mode where the device prematurely depletes its battery, leading to loss of pacing support. The identified risk control measures include enhanced battery monitoring algorithms and a clear user interface alert for low battery status. Upon re-evaluation, the residual risk associated with this failure mode remains categorized as unacceptable according to the predefined risk acceptability matrix. What is the most appropriate next step according to ISO 14971:2019?

Accepted Answer

Revisit the risk analysis to identify and implement additional risk control measures to reduce the residual risk to an acceptable level.

Question 29

A manufacturer of an implantable cardiac rhythm management device, following the successful completion of its initial risk management activities and market release, receives post-market surveillance data indicating a statistically significant increase in reports of unexpected device cessation. Preliminary investigation suggests a novel failure mechanism in a specific component not previously identified as a risk. What is the most appropriate immediate action regarding the risk management process?

Accepted Answer

Initiate a comprehensive review of the risk management file, focusing on the newly identified failure mode, its potential causes, and the adequacy of existing risk controls, and update the file accordingly.

Question 30

A manufacturer of an advanced diagnostic imaging system is preparing to release a significant software update designed to enhance image processing algorithms and improve diagnostic accuracy. This update will alter how the system interprets and displays patient data. According to the principles outlined in ISO 14971:2019, what is the mandatory action the manufacturer must undertake concerning their risk management process prior to the release of this software update?

Accepted Answer

Conduct a comprehensive review of the entire risk management file to assess the impact of the software update on identified hazards, risks, and risk control measures.

ISO 14971:2019 - Medical Device Risk Management Implementer Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 14971:2019 - Medical Device Risk Management Implementer Certification